United Therapeutics Corporation and Bio-Techne Corporation: A Detailed Gross Profit Analysis

Biotech Giants: A Decade of Profit Growth

__timestampBio-Techne CorporationUnited Therapeutics Corporation
Wednesday, January 1, 20142514110001162636000
Thursday, January 1, 20153072770001396725000
Friday, January 1, 20163366590001526100000
Sunday, January 1, 20173745410001619600000
Monday, January 1, 20184321430001429100000
Tuesday, January 1, 20194734910001331200000
Wednesday, January 1, 20204831940001375200000
Friday, January 1, 20216328500001563000000
Saturday, January 1, 20227564960001789600000
Sunday, January 1, 20237698150002070000000
Monday, January 1, 2024769725000
Loading chart...

Data in motion

A Decade of Growth: United Therapeutics vs. Bio-Techne

In the ever-evolving landscape of biotechnology, United Therapeutics Corporation and Bio-Techne Corporation have emerged as significant players. Over the past decade, from 2014 to 2023, these companies have demonstrated remarkable growth in gross profit, reflecting their strategic prowess and market adaptability.

United Therapeutics has consistently outperformed, with its gross profit peaking at approximately $2.07 billion in 2023, marking an impressive 78% increase from 2014. Meanwhile, Bio-Techne has shown a robust upward trajectory, achieving a gross profit of around $770 million in 2023, a threefold increase since 2014.

This analysis highlights the dynamic nature of the biotech industry, where innovation and strategic investments drive financial success. As we look to the future, the absence of data for United Therapeutics in 2024 leaves room for speculation, while Bio-Techne's steady growth suggests continued resilience.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025